Gastrointestinal side effects, including nausea, constipation, diarrhea, and vomiting, were the most common complaint in both groups and were generally mild to moderate, occurring mostly during the dose escalation phase.[1] Injection site reactions were more common with tirzepatide (8.6% vs
[3,4] However, at 15 g doses of l-citrulline, a lower fractional absorption rate and plasma retention of l-citrulline was observed, potentially due to saturation of its transporters (e.g., ASC or B0,+-amino acid transporters) or reduced renal conversion of l-citrulline to l-arginine
Revisiting the previous AMA on microplastics: low-effort, high-impact changes to significantly reduce microplastic exposure [1:45]
doi: 10.1093/nar/gkn132 53 van DieckJFernandez-FernandezMRVeprintsevDBFershtAR
Linh HT, Iwata Y, Senda Y, et al
Approved by the FDA in 1959, it works by stimulating the release of norepinephrine in the hypothalamus, the brain region that regulates hunger and satiety